| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium
|
Kenis, C.
|
|
|
29 |
9 |
p. 1987-1994
|
article
|
| 2 |
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
|
Mateo, J.
|
|
|
29 |
9 |
p. 1895-1902
|
article
|
| 3 |
Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies
|
Dong, X.
|
|
|
29 |
9 |
p. 2019-2020
|
article
|
| 4 |
AJCC eighth edition for soft tissue sarcoma of the extremities and trunk
|
Cates, J.M.M.
|
|
|
29 |
9 |
p. 2023
|
article
|
| 5 |
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
|
Diossy, M.
|
|
|
29 |
9 |
p. 1948-1954
|
article
|
| 6 |
Combining plasma-based biosources to predict treatment response in NSCLC patients
|
Bracht, J.W.P.
|
|
|
29 |
9 |
p. 2018
|
article
|
| 7 |
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer
|
Soria, J.-C.
|
|
|
29 |
9 |
p. 1964-1971
|
article
|
| 8 |
Editorial Board
|
|
|
|
29 |
9 |
p. ii-iii
|
article
|
| 9 |
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
|
Jones, R.L.
|
|
|
29 |
9 |
p. 1995-2002
|
article
|
| 10 |
Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study
|
Hong, R.L.
|
|
|
29 |
9 |
p. 1972-1979
|
article
|
| 11 |
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
|
Massard, C.
|
|
|
29 |
9 |
p. 1911-1917
|
article
|
| 12 |
Hodgkin lymphoma staging 50 years later: no more knives or needles!
|
Gallamini, A.
|
|
|
29 |
9 |
p. 1892-1893
|
article
|
| 13 |
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
|
Van Cutsem, E.
|
|
|
29 |
9 |
p. 1955-1963
|
article
|
| 14 |
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support
|
Lyman, G.H.
|
|
|
29 |
9 |
p. 1903-1910
|
article
|
| 15 |
Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer
|
Hanna, G.J.
|
|
|
29 |
9 |
p. 1980-1986
|
article
|
| 16 |
Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position
|
Ciccolini, J.
|
|
|
29 |
9 |
p. 1893-1894
|
article
|
| 17 |
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
|
Ettl, J.
|
|
|
29 |
9 |
p. 1939-1947
|
article
|
| 18 |
Reply to the letter to the editor ‘Age at diagnosis and prognosis among prostate cancer patients treated with radiotherapy: evidenced from three independent cohort studies’ by X. Dong, G. Ma and F. Chen
|
Pettersson, A.
|
|
|
29 |
9 |
p. 2020-2021
|
article
|
| 19 |
‘Reply to the letter to the editor ‘Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer’ by Yang et al.’ by V. Conteduca, U. De giorgi and G. Lauletta
|
Yang, D.D.
|
|
|
29 |
9 |
p. 2021-2022
|
article
|
| 20 |
Reply to the letter to the editor ‘Anti-EGFR therapy in oesophagogastric cancer: precise but not enough’ by M. Salati and S. Cascinu
|
Ruhstaller, T.
|
|
|
29 |
9 |
p. 2026
|
article
|
| 21 |
Reply to the letter to the editor ‘What type of man against machine?’ by H. Smith
|
Haenssle, H.A.
|
|
|
29 |
9 |
p. 2024-2025
|
article
|
| 22 |
Table of Contents
|
|
|
|
29 |
9 |
p. iv-vi
|
article
|
| 23 |
Targeting gamma secretase: has progress moved up a Notch?
|
Ileana Dumbrava, E.E.
|
|
|
29 |
9 |
p. 1889-1891
|
article
|
| 24 |
The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe
|
Soria, J.-C.
|
|
|
29 |
9 |
p. 1887-1888
|
article
|
| 25 |
Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment
|
Yoon, W.
|
|
|
29 |
9 |
p. 2010-2017
|
article
|
| 26 |
Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients
|
Schmidt, L.
|
|
|
29 |
9 |
p. 2003-2009
|
article
|
| 27 |
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18
|
Voltin, C.-A.
|
|
|
29 |
9 |
p. 1926-1931
|
article
|
| 28 |
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
|
de Vos, S.
|
|
|
29 |
9 |
p. 1932-1938
|
article
|
| 29 |
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
|
Basu, B.
|
|
|
29 |
9 |
p. 1918-1925
|
article
|
| 30 |
What type of man against machine?
|
Smith, H.R.
|
|
|
29 |
9 |
p. 2023-2024
|
article
|
Journal description